1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
HUMASIS Co., Ltd.

HUMASIS Co., Ltd.

KKRX:205470
2,480.00
KRW
-35.00
(-1.39%)
-1,174.36EPS
52.16BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
2,030.06
480.23
438.83
410.43
1,755.02
11,764.92
17,995.94
542.62
1,081.09
1,330.15
1,402.26
Basic EPS, GAAP
- -
1.25
31.25
72.12
-266.25
-38.75
-55
803.75
5,527.5
6,973.75
-2,175
-1,295
-690
-689.79
Free Cash Flow per Basic Share
- -
-3.75
36.59
-415.86
-270.61
-78.94
-100.46
-30.2
6,832.72
6,031.9
-3,092.18
1,002.63
428.5
470.48
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
261.15
- -
- -
- -
- -
Book Value per Share
- -
2,381.73
2,412.87
2,768.69
740.46
719.58
677.07
1,779.7
7,384.53
13,530.98
11,293.13
10,130.59
9,503.05
9,349.48
Tangible Book Value per Share
- -
2,381.73
2,412.87
1,606.09
739.42
717.64
674.52
1,778.15
7,381.73
13,526.32
11,293.13
9,925.58
9,408.49
9,191.79
Basic Weighted Avg Shares
8
2
4
4
18
22
22
26
27
26
25
24
23
23
Sales/Revenue/Turnover
- -
- -
- -
8,935
8,508
9,658
9,151
45,717
321,829
471,273
13,827
25,413
30,113
31,732
Operating Margin (%)
- -
- -
- -
-1.08
-1.61
-10.69
-9.57
55.47
60.15
45.56
-378.63
-41.55
-46.64
-44.76
Depreciation Expense
- -
- -
- -
546
398
541
595
759
1,983
4,847
4,723
2,340
3,000
3,039
Net Income, GAAP
- -
2
137
317
-4,717
-853
-1,226
20,937
151,205
182,627
-55,424
-30,442
-15,621
-15,610
Effective Tax Rate (%)
- -
22
7.92
- -
- -
- -
- -
0.12
23.14
23.12
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
3.55
-55.44
-8.83
-13.4
45.8
46.98
38.75
-400.83
-119.79
-51.87
-49.19
Working Capital
- -
11,809
11,983
2,688
14,599
20,843
10,300
32,885
159,101
254,671
218,036
131,299
129,266
101,068
LT Debt
- -
1,277
1,321
3,126
5,808
7,871
4,837
8,612
2,252
2,099
117
1,113
658
471
Total Equity
- -
10,480
10,617
12,514
15,596
16,126
15,244
48,684
202,006
346,734
287,327
249,104
235,376
238,773
Return on Invested Capital (%)
- -
- -
-0.41
- -
- -
- -
- -
56.62
96.73
51.45
- -
- -
- -
- -
Return on Capital (%)
- -
- -
1.5
- -
- -
- -
- -
46.97
114
65.91
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
1.3
2.74
-33.56
-5.38
-7.82
65.5
120.63
66.56
-17.48
-11.79
-7.03
-7.14

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11,948
11,173
13,501
LT Borrowings
338
- -
- -
LT Finance Leases
320
256
471
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
114,738
83,168
52,164

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
220,100
207,100
196,544
Cash, Cash Equivalents & STI
205,801
191,034
170,397
Accounts Receivable, Net
2,899
4,621
3,308
Inventories
5,216
4,906
4,901
Total Current Liabilities
90,834
90,273
95,477
Payables & Accruals
- -
- -
- -
ST Debt
11,948
11,173
13,501
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
61.04%
70.13%
-5.51%
Free Cash Flow
-2,538.9%
-4,842.04%
-58.84%
Net Income, GAAP
-288.11%
83.77%
-48.69%
Sales/Revenue/Turnover
- -
131.12%
18.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,869
1,098
10,538
11,908
25,413
2025
6,165
8,878
8,650
6,420
30,113
2026
8,924
7,738
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65
45
-115
-1,347.49
-1,295
2025
-75
-1,335
30.01
-377.11
-690
2026
153.23
-496
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seong-Gon Kim
Full Time Employees
64
Sector
Health technology
Industry
Medical specialties
Address
Hogye-dong, Shinwon Vision Tower Anyang-si GG South Korea 14042
IPO Date
Dec 1, 2014
Website
humasis.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Humasis Co. Ltd. Humasis Co. Ltd. (205470.KQ) develops, manufactures, and markets in vitro diagnostic medical devices and pharmaceuticals, primarily focusing on point-of-care testing (POCT) solutions in South Korea and internationally across 74 countries. The company offers comprehensive immunodiagnostic kits for quantitative and qualitative tests including cardiac markers, cancer markers, infectious diseases such as COVID-19 antigen and flu combo tests, hormones, fertility, women's health, tumor markers, and urine tests; bio-materials like COVID-19 nucleocapsid proteins, HIV surface proteins, RT-PCR kits, and Monkeypox PCR kits; diagnostic equipment encompassing urinalysis systems, blood glucose meters, and immunodiagnostic readers; and additional specialized kits such as cotinine urine tests and G6PD blood assays, totaling 163 production items. Founded in 2000 and headquartered in Anyang-si, Gyeonggi-do, South Korea, with facilities in Gunpo-si, Humasis emphasizes R&D in rapid diagnostics yielding results in 5-60 minutes and healthcare solutions integrating AI and remote platforms. Recent developments include acquiring domestic approvals for COVID-19 and influenza combo antigen tests, pursuing acquisition of Gyeongnam Pharmaceutical (Lemona) in 2024 to expand capabilities, and establishing a GMP factory branch, alongside partnerships like distribution agreements for COVID-19 products.